Tuesday, February 10, 2026 at 9:39 PM
Gilead Sciences reported strong fourth-quarter and full-year 2025 financial results, with revenue exceeding expectations and a slight increase in total product sales, indicating growth in its core business despite competitive pressures.
AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn’s disease drugs Skyrizi and Rinvoq.
Cardinal Health raised its annual outlook again after logging higher profit and revenue in its fiscal second quarter.
Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.
Cigna Group logged higher revenue in its latest quarter as its pharmacy-benefit business Evernorth continues to grow.
